60 related articles for article (PubMed ID: 21621653)
21. New non-nucleoside inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
Ivanov AV; Kozlov MV; Kuzyakin AO; Kostyuk DA; Tunitskaya VL; Kochetkov SN
Biochemistry (Mosc); 2004 Jul; 69(7):782-8. PubMed ID: 15310279
[TBL] [Abstract][Full Text] [Related]
22. The exploding field of the HCV polymerase non-nucleoside inhibitors: summary of a first generation compounds.
Tramontano E
Mini Rev Med Chem; 2008 Oct; 8(12):1298-310. PubMed ID: 18855743
[TBL] [Abstract][Full Text] [Related]
23. Antiviral therapy targeting viral polymerase.
Tsai CH; Lee PY; Stollar V; Li ML
Curr Pharm Des; 2006; 12(11):1339-55. PubMed ID: 16611119
[TBL] [Abstract][Full Text] [Related]
24. Insights into structural dynamics of allosteric binding sites in HCV RNA-dependent RNA polymerase.
Mittal L; Kumari A; Suri C; Bhattacharya S; Asthana S
J Biomol Struct Dyn; 2020 Apr; 38(6):1612-1625. PubMed ID: 31057089
[TBL] [Abstract][Full Text] [Related]
25. Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors.
Breitinger U; Farag NS; Ali NKM; Breitinger HA
Biophys J; 2016 Jun; 110(11):2419-2429. PubMed ID: 27276260
[TBL] [Abstract][Full Text] [Related]
26. Targeting structural dynamics of the RNA-dependent RNA polymerase for anti-viral strategies.
Boehr DD; Liu X; Yang X
Curr Opin Virol; 2014 Dec; 9():194-200. PubMed ID: 25224392
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C virus RNA-dependent RNA polymerase: study on the inhibition mechanism by pyrogallol derivatives.
Kozlov MV; Polyakov KM; Ivanov AV; Filippova SE; Kuzyakin AO; Tunitskaya VL; Kochetkov SN
Biochemistry (Mosc); 2006 Sep; 71(9):1021-6. PubMed ID: 17009957
[TBL] [Abstract][Full Text] [Related]
28. Polymerases of paramyxoviruses and pneumoviruses.
Fearns R; Plemper RK
Virus Res; 2017 Apr; 234():87-102. PubMed ID: 28104450
[TBL] [Abstract][Full Text] [Related]
29. Small Molecule Drugs Targeting Viral Polymerases.
Palazzotti D; Sguilla M; Manfroni G; Cecchetti V; Astolfi A; Barreca ML
Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794231
[TBL] [Abstract][Full Text] [Related]
30. Enzymatic targets in virus chemotherapy.
Helgstrand E; Oberg B
Antibiot Chemother (1971); 1980; 27():22-69. PubMed ID: 6996606
[No Abstract] [Full Text] [Related]
31. Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance.
Eltahla AA; Luciani F; White PA; Lloyd AR; Bull RA
Viruses; 2015 Sep; 7(10):5206-24. PubMed ID: 26426038
[TBL] [Abstract][Full Text] [Related]
32. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.
Eltahla AA; Tay E; Douglas MW; White PA
Antimicrob Agents Chemother; 2014 Dec; 58(12):7215-24. PubMed ID: 25246395
[TBL] [Abstract][Full Text] [Related]
33. Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection.
Aghemo A; Bhoori S; De Nicola S; Mazzaferro V; Colombo M
Hepat Mon; 2012 Jun; 12(6):411-4. PubMed ID: 22879832
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.
Tomei L; Altamura S; Bartholomew L; Bisbocci M; Bailey C; Bosserman M; Cellucci A; Forte E; Incitti I; Orsatti L; Koch U; De Francesco R; Olsen DB; Carroll SS; Migliaccio G
J Virol; 2004 Jan; 78(2):938-46. PubMed ID: 14694125
[TBL] [Abstract][Full Text] [Related]
35. A fluorescence-based high-throughput screen to identify small compound inhibitors of the genotype 3a hepatitis C virus RNA polymerase.
Eltahla AA; Lackovic K; Marquis C; Eden JS; White PA
J Biomol Screen; 2013 Oct; 18(9):1027-34. PubMed ID: 23708123
[TBL] [Abstract][Full Text] [Related]
36. Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors.
Pauwels F; Mostmans W; Quirynen LM; van der Helm L; Boutton CW; Rueff AS; Cleiren E; Raboisson P; Surleraux D; Nyanguile O; Simmen KA
J Virol; 2007 Jul; 81(13):6909-19. PubMed ID: 17459932
[TBL] [Abstract][Full Text] [Related]
37. Non-nucleoside inhibitors of the HCV polymerase.
Sarisky RT
J Antimicrob Chemother; 2004 Jul; 54(1):14-6. PubMed ID: 15190019
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research.
Haudecoeur R; Peuchmaur M; Ahmed-Belkacem A; Pawlotsky JM; Boumendjel A
Med Res Rev; 2013 Sep; 33(5):934-84. PubMed ID: 22893620
[TBL] [Abstract][Full Text] [Related]
39. RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemical properties and drug susceptibilities.
May MM; Lorengel H; Kreuter J; Zimmermann H; Ruebsamen-Schaeff H; Urban A
Biochim Biophys Acta; 2011 Oct; 1814(10):1325-32. PubMed ID: 21621653
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
